


# A novel, humanized anti-NKG2A therapeutic mAb shows a potential clinical role in humanized mouse models for the treatment of hematological malignancies



*in vitro*



*in vivo*

human primary leukemias or EBV cell lines



NOD SCID mouse

**Rescue from disease progression**

NKG2A+ NK cells pretreated with anti-human NKG2A mAb



*in vivo*

human primary leukemias or EBV cell lines



NSG mouse

CD34+ cells differentiate to NKG2A+ NK cells

anti-human NKG2A mAb



**Rescue from disease progression**